These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35054096)

  • 1. Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach.
    Rigato M; Carraro G; Cirella I; Dian S; Di Vico V; Stefanelli LF; Ravarotto V; Bertoldi G; Nalesso F; Calò LA
    J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reduced oxidative stress in ADPKD patients treated with tolvaptan].
    Rigato M; Carraro G; Cirella I; Dian S; Di Vico V; Ravarotto V; Bertoldi G; Calò LA
    G Ital Nefrol; 2022 Apr; 39(2):. PubMed ID: 35470999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of manidipine on gene expression and protein level of oxidative stress-related proteins: p22phox and HO-1: relevance for antihypertensive and anti-remodeling effects.
    Calò LA; Zaghetto F; Pagnin E; Davis PA; Semplicini A; Pessina AC
    J Cardiovasc Pharmacol; 2004 Apr; 43(4):531-8. PubMed ID: 15085064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?
    Ravarotto V; Carraro G; Pagnin E; Bertoldi G; Simioni F; Maiolino G; Martinato M; Landini L; Davis PA; Calò LA
    PLoS One; 2018; 13(9):e0204618. PubMed ID: 30261035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress reduction by icodextrin-based glucose-free solutions in peritoneal dialysis: Support for new promising approaches.
    Basso A; Baldini P; Bertoldi G; Driussi G; Caputo I; Bettin E; Cacciapuoti M; Calò LA
    Artif Organs; 2024 Sep; 48(9):1031-1037. PubMed ID: 38822597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress, inflammation, and peritoneal dialysis: A molecular biology approach.
    Innico G; Gobbi L; Bertoldi G; Rigato M; Basso A; Bonfante L; Calò LA
    Artif Organs; 2021 Oct; 45(10):1202-1207. PubMed ID: 34037984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment.
    Lee Y; Blount KL; Dai F; Thompson S; Scher JK; Bitterman S; Droher M; Herzog EL; Moeckel G; Karihaloo A; Dahl NK
    Clin Exp Nephrol; 2018 Aug; 22(4):906-916. PubMed ID: 29453607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study.
    Lai S; Mangiulli M; Perrotta AM; Gigante A; Napoleoni L; Cipolloni E; Mitterhofer AP; Gasperini ML; Muscaritoli M; Cianci R; Giovannetti A; Falco F; Mastroluca D; Mazzaferro S
    Curr Vasc Pharmacol; 2021; 19(5):556-564. PubMed ID: 32957887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients.
    Calo LA; Vertolli U; Davis PA; Maso LD; Pagnin E; Ravarotto V; Maiolino G; Lupia M; Seccia TM; Rossi GP
    Clin Nutr; 2014 Jun; 33(3):437-42. PubMed ID: 23845383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients.
    Calò LA; Naso A; Carraro G; Wratten ML; Pagnin E; Bertipaglia L; Rebeschini M; Davis PA; Piccoli A; Cascone C
    Nephrol Dial Transplant; 2007 May; 22(5):1413-9. PubMed ID: 17237480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of bempedoic acid treatment in polycystic kidney disease cells and mice.
    Hallows KR; Li H; Saitta B; Sepehr S; Huang P; Pham J; Wang J; Mancino V; Chung EJ; Pinkosky SL; Pastor-Soler NM
    Front Mol Biosci; 2022; 9():1001941. PubMed ID: 36504724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan.
    Kai H; Shinozaki Y; Nishikubo A; Watanabe M; Tawara T; Iwase M; Tsunoda R; Moriyama N; Usui T; Kawamura T; Nagai K; Hagiwara M; Saito C; Morito N; Usui J; Yamagata K
    CEN Case Rep; 2016 May; 5(1):87-90. PubMed ID: 28509176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
    Xie X; Cai Q; Guo XY; Bai DH; Sheng HZ; Wang BK; Yan K; Lu AM; Wang XR
    Comb Chem High Throughput Screen; 2020; 23(1):6-16. PubMed ID: 31793415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
    Cal LA; Maso LD; Caielli P; Pagnin E; Fusaro M; Davis PA; Pessina AC
    Blood Press; 2011 Dec; 20(6):376-82. PubMed ID: 21504378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proinflammatory/profibrotic effects of aldosterone in Gitelman's syndrome, a human model opposite to hypertension.
    Ravarotto V; Simioni F; Sabbadin C; Pagnin E; Maiolino G; Armanini D; Calò LA
    J Endocrinol Invest; 2019 May; 42(5):521-526. PubMed ID: 30136149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang J; Czerwiec FS;
    N Engl J Med; 2012 Dec; 367(25):2407-18. PubMed ID: 23121377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB
    BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.